Longevity interventions demonstrate markedly different efficacy between males and females, with response variations potentially linked to baseline lifespan differences, body composition, metabolism, and hormonal profiles. The research highlights that interventions ranging from caloric restriction to pharmacological compounds may require sex-specific optimization rather than universal application. This finding challenges the prevalent one-size-fits-all approach in aging research and clinical practice. The implications are profound for personalized longevity medicine, suggesting that optimal healthspan extension may require tailored strategies based on biological sex. Current longevity protocols, from intermittent fasting regimens to supplement dosing, likely underperform by ignoring sexual dimorphism in metabolic pathways and stress responses. The research gap is significant given that most aging studies historically skewed male or failed to analyze sex-specific outcomes. This represents a paradigm shift toward precision aging medicine, where interventions must be calibrated to leverage the distinct physiological architectures of males and females. The practical takeaway: longevity enthusiasts and clinicians should critically evaluate whether their chosen interventions have been validated in their specific sex, as the biological mechanisms driving aging and intervention responses operate through fundamentally different pathways in males versus females.